Health Technology Assessment Throughout the Drug Lifecycle
Rick A. Vreman · Utrecht University Repository (Utrecht University) · 2020
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Utrecht University Repository (Utrecht University) · Utrecht University · dissertation · 2020
Abstract
AimsThere is a trend for more flexibility in timing of evidence generation in relation to marketing authorization, including the option to complete phase III trials after authorization or not at all.This paper investigated the relation between phase II and III clinical trial efficacy in oncology.
MethodsAll oncology drugs approved by the European Medicines Agency (2007-2016) were included.Phase II and phase III trials were matched based on indication and treatment and patient characteristics.Reported objective response rates (ORR), median progression-free survival (PFS) and median overall survival (OS) were analysed through weighted mixed-effects regression with previous treatment, treatment regimen, blinding, randomization, marketing authorization type and cancer type as covariates.
ResultsA total of 81 phase II-III matches were identified including 252 trials.Mean (standard deviation) weighted difference (phase III minus II) was -4.2% (17.4) for ORR, 2.1 (6.7) months for PFS and -0.3 (5.1) months for OS, indicating very small average differences between phases.Differences varied substantially between individual indications: from -46.6% to 47.3% for ORR, from -5.3 to 35.9 months for PFS and from -13.3 to 10.8 months for OS.All covariates except blinding were associated with differences in effect sizes for at least 1 outcome.
ConclusionsThe lack of marked average differences between phases may encourage decision-makers to regard the quality of design and total body of evidence instead of differentiating between phases of clinical development.The large variability emphasizes that replication of study findings remains essential to confirm efficacy of oncology drugs and discern variables associated with demonstrated effects.32.
Open the resolved locator · 10.33540/477
Metadata licence: OpenAlex metadata (CC0)